Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
Additions to the Human Protein Atlas, available exclusively through Sigma-Aldrich, bring the portfolio to over 6,100 antibodies powered by Atlas Antibodies
This addition to the Prestige Antibodies product line is a step toward the Human Proteome Resource’s goal to develop at least one antibody to all 22,000 non-redundant human proteins by 2015.
“With this latest addition to the Prestige Antibodies line, Sigma-Aldrich has significantly expanded our antibody offerings, the latest step in our long-term plan to lead the industry in high-quality antibody content,” said Dr.
Prestige Antibodies are supported by the publicly available data of the Human Protein Atlas (HPA), part of HUPO’s Human Antibody Initiative. Multiple quality assurance testing steps ensure that Prestige Antibodies are highly specific to their targets. Each Prestige Antibody is also associated with over 500 tissue immunohistochemistry (IHC) images, over 100 cell/line immunocytochemistry (ICC) images, immunofluorescence (IF) and western blotting (WB) data, all publicly accessible via the Human Protein Atlas (www.proteinatlas.org).
Prestige Antibodies can be found at www.sigma.com/prestige, where customers can search for antibodies via specific gene name and ID, or by selecting individual chromosomes. Prestige Antibodies are also included in Sigma-Aldrich’s Your Favorite Gene powered by Ingenuity (www.sigma-aldrich.com/yfg), an award winning Web-based biological search portal for exploring dynamic gene-based content.
About Sigma-Aldrich: Sigma-
About Atlas Antibodies: Atlas Antibodies was founded in 2006 by researchers at the Royal Institute of Technology (KTH) in
Cautionary Statement: This release contains forward-looking statements relating to future strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, beliefs, intentions and the like, which involve assumptions regarding the Company’s operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.